Status:
UNKNOWN
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
Lead Sponsor:
Medical University of Warsaw
Conditions:
COPD Asthma
Eosinophilic Asthma
Eligibility:
All Genders
18-80 years
Brief Summary
Around 1/3 of patients with COPD have elevated eosinophil levels. However, the role of eosinophils in COPD has not been yet understood and is probably different in COPD and in asthma. The aim of this ...
Eligibility Criteria
Inclusion
- Diagnosis of COPD according to GOLD 2019 or asthma according to GINA 2021
- Peripheral blood eosinophil count ≥ 100 / μL
- Age ≥40 years (COPD), ≥18 years (asthma)
- History of cigarette smoking: ≥10 pack-years (for COPD)
- Stable disease period (at least 3 months without exacerbation)
- Exclusion of parasitic diseases
- Informed consent to participate in the study
Exclusion
- COPD and asthma overlap
- Use of systemic corticosteroids in the 3 months prior to the study
- Respiratory infection or exacerbation in the 3 months prior to the study
- Acute and chronic respiratory failure
- Concomitant diagnoses: systemic connective tissue diseases, malignant neoplasms, severe and / or uncontrolled cardiovascular diseases
- Use of immunosuppressive or immunomodulating drugs in the 3 months preceding the study
- Contraindications to sputum induction
- No consent to participate in the study
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05398133
Start Date
September 1 2020
End Date
June 1 2022
Last Update
May 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Warsaw, Banacha Hospital
Warsaw, Poland, 02-097